WO2005079881A1 - Procede arthroscopique d'implantation cellulaire dans des mammiferes - Google Patents

Procede arthroscopique d'implantation cellulaire dans des mammiferes Download PDF

Info

Publication number
WO2005079881A1
WO2005079881A1 PCT/DK2005/000107 DK2005000107W WO2005079881A1 WO 2005079881 A1 WO2005079881 A1 WO 2005079881A1 DK 2005000107 W DK2005000107 W DK 2005000107W WO 2005079881 A1 WO2005079881 A1 WO 2005079881A1
Authority
WO
WIPO (PCT)
Prior art keywords
defect
cells
cartilage
cell suspension
chondrocytes
Prior art date
Application number
PCT/DK2005/000107
Other languages
English (en)
Inventor
Peter Storgaard
Original Assignee
Interface Biotech A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interface Biotech A/S filed Critical Interface Biotech A/S
Publication of WO2005079881A1 publication Critical patent/WO2005079881A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/313—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
    • A61B1/317—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for bones or joints, e.g. osteoscopes, arthroscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3468—Trocars; Puncturing needles for implanting or removing devices, e.g. prostheses, implants, seeds, wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/442—Colorants, dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Definitions

  • an Arthroscopic Autologous Cell Implantation method has been designed. The method enables the orthopedic surgeon to perform arthroscopic implantation of explant-cultured cells, without open joint surgery in mammals.
  • ACI Autologous Chondrocyte Implantation
  • ACI is a clinical procedure for articular cartilage repair of the knee joint.
  • cartilage defects have been treated by cultured chondrocytes which are injected under a periosteal flap. These chondrocytes are retained within the defect, and begin to synthesize matrix components to fill the defect.
  • the newly formed matrix integrates with the surrounding host hyaline cartilage and after a certain time, solid repair tissue ("hyaline-like" cartilage) is formed in the defect.
  • the surgery method is labor intensive. Furthermore, the current ACI procedure gives the patients complications related to healing of the shine bone after harvesting of the periosteal flap as well as healing of the operated knee after open knee surgery. Other complications related to ACI are graft hypertrophy and detachment.
  • a new arthroscopic ACI method which eliminates open knee surgery, harvesting of the periosteal flap on the shinbone and the suturing of the periosteal flap to the cartilage defect, is highly warranted. Additionally, it is desirable to be able to use the ACI technology in small joints.
  • the following invention describes such a method, wherein articular cartilage and/or bone are repaired with cultured autologous chondroblast chondrocytes or osteoblast/osteocytes, which are arthroscopically implanted into a defect.
  • the objective of the invention is to provide an arthroscopic ACI treatment method of articular cartilage or bone defects in various joints in the human body or in animals.
  • the method provides a technique wherein a cell suspension is applied through a portal ("keyhole") into the articular joint, leading to sedimentation of cultured cells and adhesion of cells to subchondral bone and/or cartilage.
  • the present invention therefore relates to an endoscopic method for treating cartilage or bone defects in a subject, said method comprising the steps of: i. identifying the position of the defect, ii.
  • a cell suspension comprising cells selected from the group consisting of chondrocytes, chondroblasts, osteocytes and osteoblasts and combinations thereof into the cartilage or bone defect, the defect being positioned in such a manner that the cell suspension substantially does not flow out of the defect upon application.
  • an arthroscope When an arthroscope is used to identify the position of the defect in step i), and used to guide the injection of cultured cells in step ii), the method is known as Arthroscopic ACI.
  • Arthroscopic Autologous Cell Implantation is a medical procedure for treating cartilage or bone defects, whereby cultured cells are implanted into a defect by a catheter. This implantation procedure is visualized and guided by an arthroscope.
  • the Cell Adhesion Buffer ⁇ s intended to mean a solution that resists changes in pH and which supports an ion dependent adhesion of chondrocytes to cartilage and bone after arthroscopic implantation. It forms the liquid phase of the cell suspension which is applied to the defect. It is usually an aqueous medium, and allows the cells to be applied to the defect via a catheter or syringe while maintaining them under suitable conditions.
  • Cell Adhesion Buffer contains divalent metal-ions such as Ca 2+ , Mg 2+ , Mn 2+ which, are essential for obtaining binding between cell adhesion molecules on the cells and ligands in the matrix.
  • Various buffer systems can be used during delivery of cartilage and bone cells to the defect area.
  • Standard buffers system used in relation to this invention are; Phosphate Buffered Saline (PBS), cell culture medium (DMEM, M 199) or medium containing human (HS) or animal serum (FCS).
  • a catheter is a flexible tube, which is inserted into the body of the subject and used for introducing or removing material.
  • the catheter is used to inject cells into the defect under treatment.
  • the catheter is either anchored directly to an arthroscope or the catheter is used alone for injection of cells into the articular joint.
  • a needle may be used to introduce the cells into the defect.
  • a suspension is formed when an insoluble component mixes with a solvent.
  • a suspension is formed when the cells to be applied to the defect are mixed with the cell adhesion buffer. The suspension is then applied to the defect.
  • cation dependent way is intended to mean a binding between a cell adhesion molecule and its receptor (or ligand) which is dependent on divalent metal- ions such as Ca 2+ , Mg 2+ , and Mn 2+ .
  • matrix is intended to mean extracellular matrix proteins of the tissue such as collagens and proteoglycans. Matrix is secreted by the implanted cells (once they are bound at the defect site) and surrounds the cells. In the case of cartilage, the matrix consists mainly of collagens and proteo-glycans. In the case of bone, matrix is composed predominantly of collagens, proteo-glycans, phospho-proteins, and minerals.
  • defect area is intended to mean injured articular cartilage or bone which is surrounded by normal cartilage or bone.
  • defect cavity ⁇ s intended to mean a "hole” in articular cartilage or bone.
  • a defect cavity is created by excision of a chondral lesion during second arthroscopic operation (fig.2a) of articular cartilage or bone.
  • a defect or defect cavity may occur in cartilage or bone when it is damaged (e.g. through disease or physical injury).
  • An endoscope is a device, which can be used to look at the surface of bone or cartilage tissue without the need for open surgery (i.e. through a portal in the skin of the subject).
  • An arthroscope is a particular type of endoscope, which is used in the examination of joints.
  • An arthroscope according to the present invention is an instrument (a type of endoscope) which is inserted into a joint for visual examination.
  • An arthroscope usually comprises a tube containing fibre optics, a lens and a light source, and allows joints to be examined without open surgery.
  • Scaffold is intended to mean a temporary arrangement of proteins and/or synthetic material which may be implanted together with cells and provides a structure which they can grow around or inside. Scaffolds can provide both physical protection and structural form to the cells and support the adhesion of cells within the defect cavity.
  • viscosity is intended to mean internal friction of a moving fluid.
  • a fluid with large viscosity resists motion because molecules in the fluid gives it a lot of internal friction and vice versa, a fluid with a low viscosity flows easily because of little friction when the molecules in the fluid is in motion.
  • Viscosity is measured with a Viscometer. Viscosity is temperature dependent and typically decreases as the temperature rises. Water has a fairly low viscosity.
  • Viscosity can be measured in different units systems.
  • the SI unit is N s/m 2 , also known as the poiseuille (PI).
  • An older unit, poise (dyne s/cm 2 ) remains in common usage.10 poise equal N s/m 2 and 100 centipoise equal 1 poise.
  • One Pa s or Pascal second can also be used.
  • gel materiaf is intended to mean a solution of proteins (e.g., collagen) or other synthetic components in a more solid form than a solution.
  • a gel material may also be implanted together with cells and may provide nourishment or physical protection to the cells.
  • portaf is intended to mean a small operating procedure in which a minor hole is created in the skin in order to introduce an arthroscope as well as arthroscopic devices into articular joint.
  • carrier explanf is intended to mean a part of a mammalian articular cartilage, which has been explanted from a mammal by use of a suitable instrument.
  • An explant may contain more than one kind of tissue, e.g., in the case of explantation of tissue from the knee, the explant may contain cartilage tissue as well as bone tissue.
  • the explant can be cut into several pieces for the purpose of culturing the explant in a tissue culture flask. For some purposes it may be desirable to use a specific part of the explant. Normally, the part is collected from a mammal and used to produce one or more cell colony forming units (CFUs).
  • CFUs cell colony forming units
  • CFU Colony Forming Unit
  • CFU is intended to mean a colony of cells having the same origin, i.e., being derived from one cell such as, e.g. an cell which has migrated out from a piece of mammalian tissue explant and started divide to produce cell colonies outside the piece of mammalian tissue explant.
  • the CFUs contain several layers of cells, the first one being adhered to the surface of the tissue culture flask in which the CFU is expanded and grown.
  • the CFUs increase in size both vertically, by increasing the diameter of the CFU, and horizontally.
  • Cell adhesion is a property of in vivo or vitro cultured cells and influences cell morphology, mitosis and differentiation.
  • the sedimentation and adhesion of cultured cells to substrata is an important consideration in designing methods for implantation of autologous cultured chondrocytes, chondroblasts, osteocytes and osteoblasts.
  • substrata e.g., matrix
  • Chondroblast/chondrocyte- and osteoblast/osteocyte-matrix interaction is mediated by a series of naturally-produced adhesion molecules, which includes: Integrins, cadherins, Ig family members, selectins, syndecans and CD44.
  • Binding of cell-surface receptors to matrix ligands at the defect surface appears to be fundamental in the initial adhesion of the implanted cells.
  • Receptors on articular chondrocytes which mediate binding to these matrix molecules are for instance integrin-mediated, involving various integrin heterodimers such as ⁇ 1 ⁇ 1, ⁇ 3 ⁇ 1 ⁇ , ⁇ 5 ⁇ 1, ⁇ 10 ⁇ 1 , ⁇ v1 ⁇ 3, and ⁇ v ⁇ 5.
  • chondrocytes have been shown to adhere in vitro to articular extra-cellular matrix proteins such as type II collagen, type VI collagen, laminin, fibronectin, gamma- carboxyglutamic acid protein, chondroadherin, vitronectin, osteopontin, and bone sialo- protein.
  • cyclic RGD peptides are capable of inhibiting attachment of chondrocytes to various matrix molecules - an inhibition which is mediated through the integrins.
  • the integrin-mediated adhesion to the mentioned matrix molecules has been shown to be dependent on cations such as Ca 2+ , Mg 2+ , and Mn 2+ , being present.
  • graft cells cultured chondrocytes, chondroblasts, osteocytes and osteoblasts
  • host tissue articular cartilage and/or subchondral bone
  • factors are considered in this invention: 1) Culture conditions of cells, 2) Harvesting method of cells, 3) Suspension of harvested cells into a "Cell Adhesion Buffer", 4) Preparation of damaged and degenerated articular cartilage or bone, 5) Injection of cells through a catheter or needle into the defect cavity, 6) Sedimentation of cells to a defect area by gravity forces and 7) Final adhesion of cells to the defect area (cartilage and bone).
  • the mechanism of cell adhesion to a defect area may be influenced by the culture conditions used prior to implantation. Culture conditions affect expression of integrins, cadherins, CD44 as well as other cell adhesion molecules.
  • Figure 1a illustrates the first arthroscopic operation - harvesting of a cartilage biopsy for use in cell culturing.
  • Fig. 1b shows the front projection of the knee and arthroscopic portals.
  • Figure 2a shows the second arthroscopic operation - excision of the chondral lesion.
  • Figure 2b shows the front projection of the knee and arthroscopic portals.
  • Figure 2c shows an expanded schematic view of the excision process, using an arthroscopic shaver and scalpel.
  • Figure 3a shows an embodiment of the invention, in which the knee is bent at 110-120° so that a cell suspension can be applied to a defect cavity in the tibia plateau or in the upper femoral condyles.
  • Fig. 3b illustrates schematically the application of the cell suspension to the defect.
  • Figure 4 shows an alternative embodiment of the invention, wherein the cell suspension is injected into a defect cavity in the tibia plateau, and in which the knee is bent at ca. 90°.
  • Figure 5 shows an alternative embodiment of the invention, in which the knee is not bent, so that a cell suspension can be injected into a defect cavity in the patella or the femoral condyles.
  • Figure 6 is a schematic representation of the apparatus used in Example 1 , in which cultured porcine chondrocytes are implanted into a porcine cartilage defect using arthroscopy.
  • Figure 7 is a picture of a porcine femoral chondyle used in Example 2, showing chondrocyte sedimentation and adhesion to a full-thickness articular defect.
  • Arthroscopic Autologous Chondrocyte Implantation is a surgical method that involves fiberoptic camera technology (110) for visualizing and repairing of articular cartilage injuries with cultured chondroblast/chondrocytes or osteoblasts/osteocytes.
  • the surgeon creates 3 small portals (116) with a diameter of about 5mm through the skin and muscle, into for instance the knee joint (comprising femur (114), fibula (128), patella (132) and tibia (126)), without a larger surgical incision (fig.1a, 1b).
  • One portal (fig.1a) is created for the arthroscope (118) with magnifying lenses. Images from these lenses are sent to a television monitor (112), which the surgeon uses to monitor the procedure.
  • physiological salt water is pumped through the arthroscope using a pump (120) from a reservoir (130) into the joint, which inflates the knee joint.
  • the pumping of salt water is necessary in order to 1 ) Distend the joint, which allow the surgeon to see better and 2) Flush out any cartilage and bone debris created by the arthroscopic procedure.
  • the other two portals (116) are placed on each sides of the knee (fig.1 b). Their functions are related to removing cartilage biopsies with arthroscopic devices (122).
  • cartilage slices (100-300 mg) from e.g., a minor load-bearing area involving the upper medial femoral condyles of the knee are obtained with an arthroscopic scalpel (124).
  • the cartilage slices are stored and transported in sterile medium containing antibiotic. In a classified cell culture laboratory, the cartilage slices are further processed by the explant cell culturing method - for propagation of cartilage cells.
  • chondroblast/chondrocytes and osteoblast/osteocytes are isolated by chemotaxi stimulation in the matrix. These cells are capable of migrating in the matrix towards the articular surface and further show adherence to various matrix molecules including articular cartilage and subchondral bone surface.
  • the method is the same as that published in International Patent Application WO 02/061052 and is a production plant method of producing cell colony forming units in vitro from a mammalian tissue explant, comprising the steps of; a) growing a piece of the mammalian tissue explant in a growth medium to obtain cell colony forming units from immature cells from the piece of explant, and b) harvesting cells from one or more of the cell colony forming units for use in Autologous Cell Implantation/transplantation methods.
  • the mammalian tissue explant in the above-mentioned method may be selected from the group consisting of cartilage such as elastic, fibro, hyalin or articular hyalin cartilage and bone such as, e.g., bone marrow.
  • the present invention relates to a method for treating bone or cartilage defects as described herein, wherein the cells are obtained by: i. obtaining a tissue explant from a mammal, ii. culturing chondrocytes from said explant, iii. harvesting of said chondrocytes.
  • the cultured chondrocytes may be trypsinated before they are harvested, or between being harvested and implanted.
  • suitable cells for use in the present invention may be obtained by collagenase digestion of cartilage for isolation of chondroblast/chondrocytes in order to culture cells in a monolayer culture system or in a suspension culture system.
  • trypsination of the cultured cells is important in order to avoid steric blockade (masking) between the implanted cells and the defect surface after implantation.
  • the cells After trypsination of the cultured cells, the cells are re-suspended in a Cell Adhesion Buffer, which improves cell adhesion to the surface of the bone or cartilage.
  • the chondral lesion has to be excised as far as the normal surrounding cartilage but not as far as the subchondral bone plate.
  • the damaged/degenerated cartilage has to be removed, which may be carried out with an arthroscopic device with a cutting blade such as a scalpel (124).
  • the excision of cartilage is performed perpendicular to the articular cartilage surface (210).
  • the cutting blade (124) may be joined to the arthroscopic device (118). Salt water is pumped from a reservoir (130) using a pump (120) through the joint and out into a waste reservoir (136).
  • the surgeon may utilize a powered instrument (shaver (134)) to assist in the arthroscopic "cleaning" of articular cartilage.
  • shaver a powered instrument
  • the surgeon removes damaged cartilage in the defect. All debris from this procedure is removed with a suction device connected to the shaver (fig.2c). Only necrotic cartilage (and bone) is removed with this device in order to avoid "zone of necrosis” (cell death in cartilage caused by apoptosis and necrosis) towards healthy cartilage in the defect area. "Zone of necrosis” hinders proper binding between graft cells and host tissue.
  • Injured cartilage (212) bordering healthy cartilage (214) is only excised with an arthroscopic scalpel (124) instead of "shaving" (see fig.2c for further details on how to prepare and excise damaged cartilage for arthroscopic ACI).
  • a 1 /2-1 cm wide zone of injured cartilage is untouched before excision with the arthroscopic scalpel (fig.2c) takes place.
  • the chondral lesion(s) in a particular joint is carefully excised with the arthroscopic scalpel as far as towards healthy surrounding cartilage but not as far as the subchondral bone plate (216, fig. 2c). Excision of cartilage is done in a tourniquet controlled bloodless field, while the patient is under general anesthesia.
  • the cell suspension according to the present invention may contain ions selected from the group comprising Ca 2+ , Mn 2+ or Mg 2+ ions, or mixtures thereof.
  • the cells are therefore re-suspended in a Cell Adhesion Buffer (cell suspension) comprising autologous or heterologous serum, culture medium and divalent metal-ions such as Ca 2+ , Mg 2+ , and Mn 2+ .
  • Cell Adhesion Buffer cell suspension
  • Such ions may be present in the suspension in concentrations of 1 ⁇ M - 10mM, such as e.g.
  • the cell suspension may be made up of cells which are suspended in a medium selected from the group comprising; autologous serum, saline buffers, culture medium supplemented by divalent metal-ions.
  • the cells are autologous. Arthroscopic implantation of cells takes place 3-5 weeks after the "first arthroscopic" operation (harvesting of biopsies).
  • the cell laboratory forward to the hospital/clinic, a syringe containing a suspension of cells (3,3 x 10 6 cells/ml) in a "Cell Adhesion Buffer" containing; DMEM medium with 10% autologous serum, Fungizone, Gentamycin, Ascorbic acid 2-phosphate, supplemented by divalent metal ions reaching a final concentration for each salt as; 2mM MgCI 2 , 2mM CaCI 2 , and 0,1 mM MnCI 2 .
  • the cell suspension is composed of a 10-20% protein solution in a growth medium containing serum proteins and divalent metal ions, which do not form gel-like material, polymerize, or form other strong interactions with the cells prior to, during or after application.
  • This solution contains only single cells and "free" molecules, which do not obstruct the binding of the cells to cartilage and bone in the defect cavity.
  • Cell Adhesion Buffer a higher viscosity (relative to water) of the cell suspension (Cell Adhesion Buffer) can be obtained by adding reagents such as; NaCI, CaCI 2 , MgCI 2 , MnCI 2 , poly-L-lysine, glycerol, ficoll (non ionic synthetic polymer of sucrose), hyaloronic acid or by increasing the concentration of serum proteins in the Cell Adhesion Buffer.
  • a suitable viscosity range of the Cell Adhesion Buffer is between 0-10, such as between 0-3 mPa s at 25°C.
  • the implantation of single cells in a liquid suspension is superior compared to other ACI methods wherein for instance, cultured cells are implanted with fibrin glue, collagen gel or other gel-like materials. It is important that the cells are in suspension, as this allows them to settle into the defect under the influence of gravity. This means that no structure, scaffold, framework or other support matrix (e.g. a collagen matrix) is normally employed to support or protect the cells during implantation. If cells are implanted together with gel-like materials or other scaffolds (which is not the case in this invention), the binding between graft cells and host tissue might be hindered by the presence of "foreign" biological material. The outcome of cell implantation with gel materials or other scaffolds is poor or failure of integration of graft cells/matrix with host tissue.
  • the cell suspension which is applied to the defect, does not undergo hardening, stiffening or solidification after being applied to a defect.
  • the present invention does not require the use of binding agents such as adhesives, or the use of other binding means such as suturing of a membrane (periosteal or collagen l/lll membrane) to keep the cells within the defect.
  • the bone or cartilage defect does not need to be treated with a binding agent before application of the cells.
  • the cells themselves bring about adherence to the defect by adhesion molecules (e.g., integrins, cadhesins, CD44).
  • a (non-toxic) dye for visualization of the cell suspension during implantation can optionally be added to the Cell Adhesion Buffer.
  • a non-toxic dye e.g. food-dyes
  • Phenol Red, Alamar Blue, Brown HT, Allura Red AC or Azorubin or other azo-dyes can be added to the cell suspension prior to implantation.
  • these dyes should have no interference with the binding of the cells to cartilage and bone.
  • the cell suspension contains at least one component, which imparts colour to the suspension (i.e. a dye or colouring agent). This helps the operator of the arthroscope to visualise the cell suspension as it is applied to the defect, and to direct its flow into the defect.
  • the patient with the particular defect (310) Prior to cell implantation, the patient with the particular defect (310) is immobilised on the operating table and positioned in such a manner that the plane of the defect
  • the defect surface (measured according to the subchondral bone plate) and the operating table must be parallel to each other or at most at an angle of plus/minus 0-45°. This often means that the articular surface of the defect is substantially horizontal, i.e. with the surface parallel to the operating table/room, but can mean that the articular surface at the base of the defect is aligned for instance at most 45°, at most 30°, at most 15° to the horizontal.
  • the correct alignment is accomplished by choosing the position of the defect that gives this orientation. For instance, if an articular cartilage defect on the lateral or medial condyle of the femur (114) has to be treated with Arthroscopic ACI, then the knee is flexed (about 130°) on the patient on the operating table (316) with femur (114) in a perpendicular position relative to the operating table.
  • the scope is placed close to the cartilage defect while the outlet of the catheter (312) is placed in the defect cavity (fig. 3a, 3b, 4 and 5).
  • the flow of sterile salt-water into the joint is now turned off in order to create optimal conditions for cell sedimentation as well as cell adhesion to the various surfaces involving cartilage and subchondral bone plate.
  • the injection of cells through a portal into a defect cavity is mediated through a thin catheter or needle (312), which may be anchored to an arthroscope (118) or placed into the defect cavity (310) separately.
  • a thin catheter or needle 312
  • an arthroscope 118
  • the orthopaedic surgeon is able to follow the whole procedure during cell implantation.
  • the catheter not anchored to the scope, the surgeon is able to position (with the scope) the catheter in even smaller joints, where the arthroscope is too large for penetration. Examples of such joints are the knee, elbow, ankle, wrist, hip, shoulder, jaw, spine, finger or toe joints, or any joint in the hand or foot.
  • the defect is not necessarily completely filled with cells.
  • a syringe loaded with a 1 ml cell suspension (concentration; 3,3x10 6 cells/ml) in a Cell Adhesion Buffer is slowly emptied via the catheter into a 3,3 cm 2 defect cavity (fig.3b).
  • the arthroscope and catheter are now carefully removed from the joint.
  • the arthroscope and catheter can also be removed later in the process, if desirable.
  • the cells After injection of the cells into the defect cavity, the cells are allowed to settle
  • the cells After implantation, the cells synthesize matrix proteins such as collagens and proteoglycans, which mediate the first binding (covalent as well as non-covalent) to the adjacent hyaline cartilage. This binding is highly critical for the successful outcome of the repair process.
  • Final adhesion of cells to the subchondral bone and cartilage takes place over a period of from 1 minute to 24 hours, such as e.g. from 5 minutes to 12 hours, from 15 minutes to 6 hours, from 30 minutes to 3 hours, from 45 minutes to 2 hours, from 50 minutes to 90 minutes such as e.g. 60 min.
  • the defect is held substantially immobile, while adhesion of cells to subchondral bone and cartilage increases with time. After this period, the cells are resistant to detachment by gravitational forces and other handling. After this time period, the portals are closed.
  • the ideal number of cells per square centimetre in the defect after adherence to the defect is from 1x10 5 to 1x10 7 cells/cm 2 , and the cells in the cell suspension are present in a concentration of 1x10 5 to 1x10 7 cells/ml, such as e.g. 1x10 5 to 5x10 6 cells/ml, 5x10 5 to 5x10 6 cells/ml, 1x10 6 to 5x10 6 cells/ml.
  • integrins In this context, it has been shown that the binding of integrins to certain matrix proteins are dependent on cations such as Ca 2+ , Mg 2+ , and Mn 2+ and further, that binding between integrins and ligands (matrix proteins) are blocked with cyclic synthetic peptides containing a RGD recognition motif.
  • the chondrocytes are re-suspended in the Cell Adhesion Buffer containing e.g. 2 mM MgCI 2 , 0.1 mM MnCI 2 , 2 mM CaCI 2 , in DMEM/F12 medium containing 10 % autologous serum.
  • the surgically treated defect should be immobilized for a short period of about 1-48 hours after the cells have been allowed to settle, such as e.g. 2-36 hours, 5-24 hours or 10-24 hours and further protected from strong motion and loading for a similar amount of time in order for the cells to secrete matrix into the defect area, which will mediate binding to the adjacent bone or cartilage as well as protecting the implanted cells from mechanical disturbance.
  • This further immobilisation usually means that the patient is confined to a bed and active movement of the articular joint without weight bearing is only initiated after this period.
  • immobilization of the defect can have any angle. It is only during application of the cell suspension that immobilization of the joint (at a particular angle) has to take place, in order to secure proper sedimentation of the cells in the defect area.
  • conventional ACI uses a periosteal flap or patch to cover the cells and keep them in the defect.
  • the method according to the present invention allows treatment or repair of cartilage or bone defects without the use of a periosteal flap/patch, as the cells settle into the defect under the influence of gravity and adhere to the cartilage or bone while the defect is immobilised.
  • Suitable subjects for treatment under the method according to the present invention are mammals, such as human, horse, camel, dog or cat.
  • a left hind limb (610) from a healthy one-year old pig was obtained from a local slaughterhouse (Steff Houlberg/Danisco, Ringsted, Denmark).
  • the limb was transported to the laboratory in a cooling box (with ice) prior to the experiment.
  • the limb was anchored to a rack (612) with various catchers (614) according to fig.6.
  • the limb was placed upside down in the rack with the femoral condyles pointing upwards.
  • the special orientation of the limb was arranged in order to orientate part of the femur condyles parallel with the operating table.
  • Two small incisions were made anterolateral and anteromedial in the porcine knee.
  • One incision was used for the catheter (312) and the scope (118) with a "two-connect sheath system" (Linvatec's pressure sensing pump systems, QuicklatchTM) according to fig.6.
  • the second incision was used for the outflow tubing of the fluid.
  • a third incision was made on the lateral side of the porcine knee, distal to the other two portals.
  • the third portal (116) was used for arthroscopic devices for creating a full-thickness articular defect into the femoral condyle.
  • the pump (120) was turned on in order to flow saline from a reservoir (130) into the knee joint and out into a waste container (136).
  • a one cm 2 full-thickness cartilage defect was created in both the lateral and medial femoral condyles using arthroscopic devices and a scope (118) (QuicklatchTM) connected with a camera head (110) (EnVision TM).
  • cartilage was excised to the subchondral bone with an arthroscopic scalpel (in example 1 , an arthroscopic shaver was not used).
  • the full-thickness cartilage defects were made perpendicular to the cartilage surface and all cartilage was removed towards the subchondral zone as shown in fig.2c.
  • Cartilage biopsies taken out with the arthroscopic device were dissected with a scalpel under sterile conditions in a cell culture laboratory. Each cartilage specimen was further divided into smaller pieces by cutting perpendicular to the articular surface. Explants, measuring about 5 x 5 x 3-5 mm, were used in the following experiments for propagation of chondrocytes. Explants were cultured in 75 cm 2 cell culture flasks (InVitrogen) (5 explants in each flask).
  • Dubelcco's Modified Eagle's Medium DMEM/NUT.MIX.F-12 medium with Glutamax-1 (InVitrogene) with 20 % Fetal Calf Serum (FCS) (Life Technologies)
  • Gentamycin 49 ug/ml
  • Fungizone 1,2 ug/ml
  • Ascorbic acid 2-phosphate 87 ug/ml
  • Reagents were obtained from Sigma Aldrich.
  • Fresh medium was added every 3rd day to all explants in order to stimulate chondrocytes in the explants for migration (chemotaxi) into the culture medium following chondrocyte proliferation and formation of Colony Forming Units (CFU).
  • CFU Colony Forming Units
  • the optimal concentration of chondrocytes adhering to a 1cm 2 cartilage defect was in example 2 (see below) estimated to be 1x10 6 chondrocytes/cm 2 . This means that a total concentration of 3,3x10 6 chondrocytes/ml is needed in the final chondrocyte suspension for implantation.
  • Porcine left hind limbs from "healthy" one-year-old pigs were obtained from a local slaughter-house (Steff Houlberg/Danisco, Ringsted, Denmark).
  • the femoral condyles (718) were "amputated” from the exposed knees with a saw and a scalpel.
  • An amputated condyle is shown in fig.7 (718).
  • the femoral condyles obtained by this procedure were used in the following experiment, 3 hours after the pigs were slaughtered.
  • Porcine chondrocytes were cultured according to the explant cell culturing method described in example 1. In short, 10x10 6 porcine chondrocytes were harvested from a 75 cm 2 culture flask with 0,25%trypsin/EDTA and re-suspended in a Cell Adhesion Buffer" (1ml) as described in example 1.
  • the chondrocyte suspension containing 10x10 6 chondrocytes/ml was carefully loaded into a 1 ml syringe with a 16 Gauge needle.
  • the syringe was placed into a 37°C incubator supported with 5% CO 2 prior to in vitro implantation.
  • a 1 cm 2 full-thickness cartilage defect (710) was created in the middle of the medial and lateral femoral condyles using a sterile scalpel (fig.7).
  • the full-thickness cartilage defects (710) were made perpendicular to the cartilage surface and all cartilage was removed towards the subchondral bone plate (712, fig.7).
  • the femoral condyles were washed in DMEM/F12 medium and transferred into sterile petri dishes (714) containing DMEM/F12 medium with 10% porcine serum (716). The petri dishes (with lid on) were then transferred into a 37°C incubator supported with 5% CO 2 . The femoral condyles with the defect area pointing upwards and parallel to the table were equilibrated in the incubator for 1 hour. These conditions were selected in order to imitate physiological conditions.
  • the petri dish was incubated for 1 hour at 37°C in order to obtain sedimentation and adherence of the chondrocytes into the defect cavity. After 1 hour of incubation, the femoral condyles loaded with explant-cultured chondrocytes were washed several times in the petri dish with 37°C Cell Adhesion Buffer in order to remove "non-binding" chondrocytes in the defect cavity.
  • each femoral condyle was transferred into separate 50 ml Falcon tubes filled with DMEM/F12 medium containing 10% porcine serum.
  • the filled tubes were anchored to a horizontal shaker in the CO 2 incubator and set to "level 1" for 60 minutes.
  • Results showed that an average number of 1x10 6 chondrocytes pr cm 2 full-thickness defect was obtained after harvesting chondrocytes from several 1cm 2 defect cavities, in order to release the cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention se rapporte à un procédé endoscopique permettant de traiter des défauts cartilagineux ou osseux chez un mammifère, ledit procédé comprenant les étapes consistant (i) à identifier la position du défaut, et (ii) à appliquer une suspension cellulaire comprenant des cellules sélectionnées dans le groupe constitué par des chondrocytes, des chondroblastes, des ostéocytes et des ostéoblastes ainsi que des combinaisons de ces cellules, dans le défaut cartilagineux ou osseux, ledit défaut étant positionné de sorte que la suspension cellulaire ne s'écoule sensiblement pas à l'extérieur dudit défaut lors de l'application.
PCT/DK2005/000107 2004-02-19 2005-02-18 Procede arthroscopique d'implantation cellulaire dans des mammiferes WO2005079881A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400260 2004-02-19
DKPA200400260 2004-02-19

Publications (1)

Publication Number Publication Date
WO2005079881A1 true WO2005079881A1 (fr) 2005-09-01

Family

ID=34878002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000107 WO2005079881A1 (fr) 2004-02-19 2005-02-18 Procede arthroscopique d'implantation cellulaire dans des mammiferes

Country Status (1)

Country Link
WO (1) WO2005079881A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063267A1 (fr) * 2009-11-20 2011-05-26 Knee Creations, Llc Instruments destinés à une approche à angles variables d'une articulation
US8801800B2 (en) 2009-11-20 2014-08-12 Zimmer Knee Creations, Inc. Bone-derived implantable devices and tool for subchondral treatment of joint pain
US8821504B2 (en) 2009-11-20 2014-09-02 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
US8864768B2 (en) 2009-11-20 2014-10-21 Zimmer Knee Creations, Inc. Coordinate mapping system for joint treatment
US8951261B2 (en) 2009-11-20 2015-02-10 Zimmer Knee Creations, Inc. Subchondral treatment of joint pain
US9033987B2 (en) 2009-11-20 2015-05-19 Zimmer Knee Creations, Inc. Navigation and positioning instruments for joint repair
US9259257B2 (en) 2009-11-20 2016-02-16 Zimmer Knee Creations, Inc. Instruments for targeting a joint defect
US9271835B2 (en) 2009-11-20 2016-03-01 Zimmer Knee Creations, Inc. Implantable devices for subchondral treatment of joint pain
WO2019155434A1 (fr) 2018-02-09 2019-08-15 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Dispositif médical pour l'administration de formulations thérapeutiques et méthodes d'utilisation de celui-ci
CN114466923A (zh) * 2019-08-02 2022-05-10 阿尔塞克有限责任公司 一种体外培养软骨细胞和软骨以获得治疗关节软骨缺损材料的方法
WO2023022941A1 (fr) * 2021-08-20 2023-02-23 Vericel Corporation Méthodes de réparation de défauts cartilagineux
US11857170B2 (en) 2022-03-04 2024-01-02 Vericel Corporation Methods and devices for repairing cartilage defects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001006949A2 (fr) * 1999-07-28 2001-02-01 Interface Biotech A/S Reparation in vivo de defauts osseux et/ou du cartilage
US20010051834A1 (en) * 1999-03-24 2001-12-13 Chondros, Inc. Method for composite cell-based implants
WO2002061052A2 (fr) * 2001-01-31 2002-08-08 Interface Biotech A/S Procede perfectionne de culture de cellules de mammifere in vitro pour des procedes d'implantation/de transplantation de cellules autologues
WO2004110512A2 (fr) * 2003-06-12 2004-12-23 Interface Biotech A/S Methode d'implantation de cellules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051834A1 (en) * 1999-03-24 2001-12-13 Chondros, Inc. Method for composite cell-based implants
WO2001006949A2 (fr) * 1999-07-28 2001-02-01 Interface Biotech A/S Reparation in vivo de defauts osseux et/ou du cartilage
WO2002061052A2 (fr) * 2001-01-31 2002-08-08 Interface Biotech A/S Procede perfectionne de culture de cellules de mammifere in vitro pour des procedes d'implantation/de transplantation de cellules autologues
WO2004110512A2 (fr) * 2003-06-12 2004-12-23 Interface Biotech A/S Methode d'implantation de cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIJNISSEN W J C M ET AL: "Tissue-engineered cartilage using serially passaged articular chondrocytes. Chondrocytes in alginate, combined in vivo with a synthetic (E210) or biologic biodegradable carrier (DBM) - microbial adhesion versus tissue integration", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 6, March 2000 (2000-03-01), pages 571 - 580, XP004187175, ISSN: 0142-9612 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9351835B2 (en) 2009-11-20 2016-05-31 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
US9717544B2 (en) 2009-11-20 2017-08-01 Zimmer Knee Creations, Inc. Subchondral treatment of joint pain
US8801800B2 (en) 2009-11-20 2014-08-12 Zimmer Knee Creations, Inc. Bone-derived implantable devices and tool for subchondral treatment of joint pain
US8821504B2 (en) 2009-11-20 2014-09-02 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
US8864768B2 (en) 2009-11-20 2014-10-21 Zimmer Knee Creations, Inc. Coordinate mapping system for joint treatment
US8906032B2 (en) 2009-11-20 2014-12-09 Zimmer Knee Creations, Inc. Instruments for a variable angle approach to a joint
US8951261B2 (en) 2009-11-20 2015-02-10 Zimmer Knee Creations, Inc. Subchondral treatment of joint pain
US9033987B2 (en) 2009-11-20 2015-05-19 Zimmer Knee Creations, Inc. Navigation and positioning instruments for joint repair
US9119721B2 (en) 2009-11-20 2015-09-01 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
CN102740784B (zh) * 2009-11-20 2015-09-09 膝部创造物有限责任公司 用于对关节的可变角度进路的仪器
US9259257B2 (en) 2009-11-20 2016-02-16 Zimmer Knee Creations, Inc. Instruments for targeting a joint defect
US9271835B2 (en) 2009-11-20 2016-03-01 Zimmer Knee Creations, Inc. Implantable devices for subchondral treatment of joint pain
US9386996B2 (en) 2009-11-20 2016-07-12 Zimmer Knee Creations, Inc. Navigation and positioning instruments for joint repair
US9351746B2 (en) 2009-11-20 2016-05-31 Zimmer Knee Creations, Inc. Coordinate mapping system for joint treatment
WO2011063267A1 (fr) * 2009-11-20 2011-05-26 Knee Creations, Llc Instruments destinés à une approche à angles variables d'une articulation
US9439765B2 (en) 2009-11-20 2016-09-13 Zimmer Knee Creations, Inc. Method for subchondral treatment of joint pain using implantable devices
CN102740784A (zh) * 2009-11-20 2012-10-17 膝部创造物有限责任公司 用于对关节的可变角度进路的仪器
US9730744B2 (en) 2009-11-20 2017-08-15 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
US10271883B2 (en) 2009-11-20 2019-04-30 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
US11006992B2 (en) 2009-11-20 2021-05-18 Zimmer Knee Creations, Inc. Method for treating joint pain and associated instruments
WO2019155434A1 (fr) 2018-02-09 2019-08-15 Stemmatters, Biotecnologia e Medicina Regenerativa, S.A. Dispositif médical pour l'administration de formulations thérapeutiques et méthodes d'utilisation de celui-ci
CN114466923A (zh) * 2019-08-02 2022-05-10 阿尔塞克有限责任公司 一种体外培养软骨细胞和软骨以获得治疗关节软骨缺损材料的方法
WO2023022941A1 (fr) * 2021-08-20 2023-02-23 Vericel Corporation Méthodes de réparation de défauts cartilagineux
US11857170B2 (en) 2022-03-04 2024-01-02 Vericel Corporation Methods and devices for repairing cartilage defects

Similar Documents

Publication Publication Date Title
WO2005079881A1 (fr) Procede arthroscopique d'implantation cellulaire dans des mammiferes
Wakitani et al. Repair of articular cartilage defects in the patello‐femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees
Butler et al. The use of mesenchymal stem cells in collagen-based scaffolds for tissue-engineered repair of tendons
Al Faqeh et al. The potential of intra-articular injection of chondrogenic-induced bone marrow stem cells to retard the progression of osteoarthritis in a sheep model
JP4959916B2 (ja) 関節軟骨損傷治療用組成物
JP5656183B2 (ja) 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用
CN101505796A (zh) 使用干细胞产物进行软组织修复和再生
Kim et al. Rotator cuff bridging repair using acellular dermal matrix in large to massive rotator cuff tears: histologic and clinical analysis
Li et al. Transplantation of Cbfa1-overexpressing adipose stem cells together with vascularized periosteal flaps repair segmental bone defects
Korthagen et al. A short-term evaluation of a thermoplastic polyurethane implant for osteochondral defect repair in an equine model
CN106421917A (zh) 制备用于软骨损伤修复的组合物的方法
CN105754937A (zh) 一种促进软骨分化的细胞共培养体系及其制备方法
CN106309493A (zh) 一种软骨干细胞制剂及其制备方法和应用
CN108096633A (zh) 一种软骨缺损修复材料及其制备方法
US20190307928A1 (en) Polymeric patch scaffolds for articular cartilage regeneration
CN103874763A (zh) 从胎儿组织制备亲代细胞库
Monzavi et al. Extracellular matrix scaffold using decellularized cartilage for hyaline cartilage regeneration
Harris et al. Minced cartilage techniques
Libera et al. Cartilage engineering
Peng et al. Combination of a human articular cartilage-derived extracellular matrix scaffold and microfracture techniques for cartilage regeneration: A proof of concept in a sheep model
CN106421918A (zh) 软骨细胞组合物
Gobbi et al. Next generation cartilage solutions
US20200171215A1 (en) Formation of stable cartilage
RU2351020C1 (ru) Способ лечения полнослойных дефектов хряща коленного сустава с использованием культуры аутологичных мезенхимальных стволовых клеток
RU2800991C2 (ru) Способ биофабрикации трансплантата в виде клеточных сфероидов для регенеративных технологий восстановления хряща субъекта на основе надхрящницы собственного реберного хряща субъекта и мультипотентных мезенхимальных стромальных клеток костного мозга этого же субъекта

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase